Sign in

CIK 0001714899

  • Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
463872213
Phone
+1 650-866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Derivatives Options or other derivatives
  2. 4 Grant or award President and CEO acquired 5 shares (grant or award)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Open-market buy 10% owner bought 275,000 shares at $18.00 ($4,950,000)
  5. 4 Conversion FIL Ltd acquired 3,273,807 shares (conversion)
  6. 4 Conversion FMR LLC acquired 3,238,676 shares (conversion)
  7. 4 Conversion 10% owner acquired 8,606,249 shares (conversion)
  8. 4 Conversion 10% owner acquired 10,756,249 shares (conversion)
  9. 4 Conversion Director acquired 25,000 shares (conversion)
  10. 4 Conversion Director acquired 249,998 shares (conversion)
  11. 4 Conversion Director acquired 62,500 shares (conversion)
  12. 4 Conversion Director acquired 10,756,249 shares (conversion)
  13. 4 Conversion Director acquired 250,000 shares (conversion)
  14. 4 Conversion CFO and Treasurer acquired 500,000 shares (conversion)
  15. 4 Conversion President and CEO acquired 12,500 shares (conversion)
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 21 of 22 · 436 filings